Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
TITAN trial yields big survival benefits in mCSPC
Key clinical point: Combined androgen-binding inhibitor and androgen deprivation therapy extends survival of castration-sensitive prostate cancer.
Major finding: The overall survival rate at 24 months was 82.4% in the apalutamide group, compared with 73.5% in the placebo group.
Study details: Randomized phase 3 trial in 1052 men with metastatic castration-sensitive prostate cancer.
Disclosures: The TITAN trial was supported by Aragon Pharmaceuticals. Dr. Chi disclosed grants and personal fees from multiple companies, not including Aragon. Dr. Carducci disclosed consulting or advisory roles and institutional research funding from multiple companies, not including Aragon.
Chi KN et al, ASCO 2019 Abstract 5006. N Engl J Med doi: 10.1056/NEJMoa1903307.